Ingvild Birschmann

Dr. Ingvild Birschmann


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
TEThomas Eller
Thomas Eller
JBJessica Busse
Jessica Busse
MDMarcus Dittrich
Marcus Dittrich
TFTobias Flieder
Tobias Flieder
SASusanne Alban
Susanne Alban
IBIngvild Birschmann
Ingvild Birschmann
Background: In recent years, several selectively acting anticoagulants, including the direct thrombin inhibitors (DTI; argatroban, dabigatran) and the factor Xa inhibitors (rivaroxaban, apixaban, fondaparinux), have been developed. With their clinical application increasing, it is of interest to evaluate their interference with classical haemostaseological point-of-care tests. Additionally, the effect of the investigated anticoagulants on platelet function tests will come increasingly more into focus for monitoring not only hereditary platelet dysfunction, but also antiplatelet therapy. Methods: Blood samples from healthy volunteers were spiked with therapeutic and supratherapeutic concentrations of the drugs listed above and investigated with regard to their effects on the following POCTs: activated clotting time (ACT), thromboelastometry with ROTEM®, PFA® and Multiplate®. Light-transmission aggregometry (LTA) was used for a platelet function assay. Results: At supratherapeutic concentrations, ACT and ROTEM® analysis were always influenced after administration of the drugs listed above (except fondaparinux in EXTEM-CT). Therapeutic concentrations showed differential effects on these assays. LTA measurements revealed a distinct decrease in α-thrombin-induced platelet aggregation for both DTIs (therapeutic and supratherapeutic concentrations), while argatroban reduced platelet function in supratherapeutic concentrations. None of the drugs seemed to have any influence on PFA® or Multiplate®. Conclusions: Selective thrombin and factor Xa inhibitors exhibit distinct effects on POCTs and platelet function tests. This must be considered in assessing assay results when taking medical decisions.

1 January 2014 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
IBIngvild Birschmann
Ingvild Birschmann
MDMarcus Dittrich
Marcus Dittrich
TEThomas Eller
Thomas Eller
BWBettina Wiegmann
Bettina Wiegmann
ARArmin J. Reininger
Armin J. Reininger
MSMartin Strüber
Martin Strüber

15 February 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
MEMatthias Ebner
Matthias Ebner
IBIngvild Birschmann
Ingvild Birschmann
APAndreas Peter
Andreas Peter
CSCharlotte Spencer
Charlotte Spencer
FHFlorian Härtig
Florian Härtig
SPSven Poli
Sven Poli
Point-of-care testing (POCT) of coagulation has been proven to be of great value in accelerating emergency treatment. Specific POCT for direct oral anticoagulants (DOAC) is not available, but the effects of DOAC on established POCT have been described. We aimed to determine the diagnostic accuracy of Hemochron® Signature coagulation POCT to qualitatively rule out relevant concentrations of apixaban, rivaroxaban, and dabigatran in real-life patients. We enrolled 68 patients receiving apixaban, rivaroxaban, or dabigatran and obtained blood samples at six pre-specified time points. Coagulation testing was performed using prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), and activated clotting time (ACT+ and ACT-low range) POCT cards. For comparison, laboratory-based assays of diluted thrombin time (Hemoclot) and anti-Xa activity were conducted. DOAC concentrations were determined by liquid chromatography-tandem mass spectrometry. Four hundred and three samples were collected. POCT results of PT/INR and ACT+ correlated with both rivaroxaban and dabigatran concentrations. Insufficient correlation was found for apixaban. Rivaroxaban concentrations at <30 and 95% specificity at PT/INR POCT ≤1.0 and ≤1.1 and ACT+ POCT ≤120 and ≤130 s. Dabigatran concentrations at <30 and 95% specificity at PT/INR POCT ≤1.1 and ≤1.2 and ACT+ POCT ≤100 s. Hemochron® Signature POCT can be a fast and reliable alternative for guiding emergency treatment during rivaroxaban and dabigatran therapy. It allows the rapid identification of a relevant fraction of patients that can be treated immediately without the need to await the results of much slower laboratory-based coagulation tests. Unique identifier, NCT02371070 . Retrospectively registered on 18 February 2015.

25 February 2021 in Transplantation
Verified
Journal Article
Closed access
FKFranziska Msc Knüttgen
Franziska Msc Knüttgen
JBJulia Beck
Julia Beck
MDMarcus Dittrich
Marcus Dittrich
MOMichael Oellerich
Michael Oellerich
AZArmin Zittermann
Armin Zittermann
IBIngvild Birschmann
Ingvild Birschmann
Background.: Circulating graft-derived cell-free DNA (dd-cfDNA) is a new marker of cardiac allograft damage that is used for noninvasive rejection diagnostics. We performed dd-cfDNA (%) in heart transplant recipients during the first posttransplant year. Methods.: In 87 patients, serial dd-cfDNA determination at predefined time-points was performed in 770 single samples. dd-cfDNA fraction (%) was measured using an established universal droplet digital polymerase chain reaction method, providing same-day turn-around. Rejection was diagnosed according to clinical parameters and biopsies. Results.: Median dd-cfDNA (%) was high (5.36%) immediately after reperfusion and decreased to a median (interquartile range) of 0.10% (0.05%–0.24%) in clinically stable patients by postoperative day 10. Compared to dd-cfDNA (%) samples in clinically stable patients, values were higher (P < 0.001) in biopsy-proven rejection ISHLT 1R (0.42% [0.15%–0.53%]) and 2R rejection (0.84% [0.39%–0.97%]). Moreover, dd-cfDNA (%) was already significantly increased 9–30 days before biopsy-proven rejection (0.36% [0.20%–0.61%]). An as yet unknown finding was a slightly, but significantly (P < 0.0001) higher dd-cfDNA (%) value in samples of stable patients with pericardial effusions (PEs) (n = 94; 0.18% [0.07%–0.30%]) compared to samples of non-PE patients (n = 132; 0.07% [0.04%–0.17%]). Using a cutoff of 0.35%, sensitivity and specificity of dd-cfDNA for cardiac rejection were 0.76 and 0.83 (area under the curve [AUC] ROC-curve: 0.81 [95% confidence interval, 0.73-0.89]). Omitting PE samples from the control group yielded an AUC of 0.86 [95% confidence interval, 0.76-0.95]. Samples drawn <12 hours after endomyocardial biopsy showed high (0.40% [0.15%–1.21%]) dd-cfDNA values, also in ISHLT0R (0.36% [0.10%–0.60%]). Conclusions.: dd-cfDNA plasma values were significantly associated with cardiac rejection. However, PE or improper sampling (eg, shortly after biopsy) should be considered as confounders for rejection diagnoses using dd-cfDNA.

1 May 2018 in Thrombosis Research
Verified
Journal Article
Closed access
TFT. Flieder
T. Flieder
MWM. Weiser
M. Weiser
TETh. Eller
Th. Eller
MDM. Dittrich
M. Dittrich
KBK. von Bargen
K. von Bargen
IBIngvild Birschmann
Ingvild Birschmann

29 September 2021 in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
Edelgard Lindhoff-LastEdelgard Lindhoff-Last
Edelgard Lindhoff-Last
IBIngvild Birschmann
Ingvild Birschmann
JKJoachim Kuhn
Joachim Kuhn
SLSimone Lindau
Simone Lindau
SKStavros Konstantinides
Stavros Konstantinides
OROn behalf of the RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry)
On behalf of the RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry)
Background Direct oral anticoagulants (DOACs) are increasingly used worldwide. Little is known so far about their pharmacokinetics in emergency situations. Methods A prospective, observational registry was performed to determine the clinical course in consecutive patients with major bleeding or urgent surgery treated with DOACs. In samples collected as part of routine care DOAC drug concentrations were measured using ultraperformance liquid chromatography-tandem mass spectrometry. Anticoagulant intensity at first presentation and drug half-life (t 1/2), tested in repeat samples, were evaluated. Results A total of 140 patients were prospectively included. Pharmacokinetic data were available in 94% (132/140) of patients. Note that 67% (89/132) experienced life-threatening bleeding and 33% (43/132) needed an urgent surgery. For pharmacokinetic analysis a total of 605 blood samples was available. Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban. All treatment groups showed a high variation of drug concentrations at baseline. In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4–19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7–19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2–27.9; p = 0.292). In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9–27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9–36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8–23.2; p < 0.001). Conclusion Emergency patients under DOAC treatment show a high variation of anticoagulant concentrations at baseline. Compared with rivaroxaban, apixaban showed a lower median concentration on admission and a longer t ½. E.L.-L. was responsible for the conceptualization and the methodology of the RADOA-registry, organized funding acquisition, and wrote the original draft preparation. I.B. performed the mass spectrometry analysis of the DOAC-levels and reviewed major parts of the manuscript. J.K. performed the mass spectrometry analysis of the DOAC-levels. S.L., S.K., O.G., U.N.-G., B.Z., C.v.H., I.B., A.S., J.B.-W., S.S., P.M., and A.G. recruited patients and supported the writing of the manuscript. J.L. and B.Z. were responsible for the project administration. E.H. performed the statistical analysis and was responsible for the validation and visualization of the results. All the authors have read and agreed to the published version of the manuscript. The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Boards of all participating hospitals. For informed consent statements see Ethics as part of the Material and Methods section of the manuscript. ClinicalTrials.gov Identifier: NCT01722786 (URL: https://clinicaltrials.gov/ct2/show/NCT01722786?term=lindhoff-last&rank=9). * Both the authors contributed equally to the study. Received: 19 March 2021 Accepted: 25 June 2021 Accepted Manuscript online: 13 July 2021 Article published online: 29 September 2021 © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany